hyperboy262626
6 months ago
https://finance.yahoo.com/news/rafarma-pharmaceutical-updates-registration-rafarma-133000510.html
Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.
Currently, procedure is underway to register Yttrium 90 microspheres produced by Rafarma in South Korea, with a view to their subsequent pharmaceutical distribution in Korea. South Korea is the only Asian country with health insurance to use yttrium 90 microspheres for liver cancer patients.
Nanostructured Rafarma microspheres are intended for the treatment of liver cancer, and can also be used for radioembolization of other solid tumors.
Rafarma develops and implements a variety of radionuclide therapy technologies for the treatment of liver cancer and other solid tumors, which can provide a higher quality of life for the patient and delay the development of the disease.
The main idea of ??radionuclide therapy is the delivery of radioactive isotopes directly to the tumor and its subsequent destruction by ionizing radiation. Similar treatment technologies with different methods of delivering radionuclides have been successfully used to treat various diseases.
The principle of action of microspheres: embolization (blockage) of tumor vessels; selective accumulation in the tumor and its destruction by targeted irradiation; microspheres with Yttrium-90 are administered intra-arterially, which ensures that the maximum number of tumor foci is affected, so it is advisable to use them for the treatment of metastases.
Advantages of using microspheres: minimally invasive administration process; minimal damage to healthy tissue; damage to all foci and metastases of the tumor at once; the ability to deliver almost any dose of radiation to the tumor.
Efficiency of use: the average survival of patients when using microspheres with yttrium and chemotherapy increased from 13 to 27 months compared with the use of chemotherapy alone; 89% of patients have a positive response to treatment; 27% experience a decrease in tumor size.
Eurotradr
6 months ago
Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea
July 04, 2024 09:30 ET | Source: Rafarma Pharmaceuticals Inc.
Share
Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.
Currently, procedure is underway to register Yttrium 90 microspheres produced by Rafarma in South Korea, with a view to their subsequent pharmaceutical distribution in Korea. South Korea is the only Asian country with health insurance to use yttrium 90 microspheres for liver cancer patients.
Nanostructured Rafarma microspheres are intended for the treatment of liver cancer, and can also be used for radioembolization of other solid tumors.
Rafarma develops and implements a variety of radionuclide therapy technologies for the treatment of liver cancer and other solid tumors, which can provide a higher quality of life for the patient and delay the development of the disease.
The main idea of ??radionuclide therapy is the delivery of radioactive isotopes directly to the tumor and its subsequent destruction by ionizing radiation. Similar treatment technologies with different methods of delivering radionuclides have been successfully used to treat various diseases.
The principle of action of microspheres: embolization (blockage) of tumor vessels; selective accumulation in the tumor and its destruction by targeted irradiation; microspheres with Yttrium-90 are administered intra-arterially, which ensures that the maximum number of tumor foci is affected, so it is advisable to use them for the treatment of metastases.
Advantages of using microspheres: minimally invasive administration process; minimal damage to healthy tissue; damage to all foci and metastases of the tumor at once; the ability to deliver almost any dose of radiation to the tumor.
Efficiency of use: the average survival of patients when using microspheres with yttrium and chemotherapy increased from 13 to 27 months compared with the use of chemotherapy alone; 89% of patients have a positive response to treatment; 27% experience a decrease in tumor size.
ABOUT RAFARMA PHARMACEUTICALS
Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields at the moment.
For more information, please visit https://www.noyarp.com
CONTACTS:
RAFARMA PHARMACEUTICALS
babenko_press@rafapharm.com
+1 (307) 218-0292
Sheridan, Wyoming, 82801, USA
Source: Rafarma Pharmaceuticals, Inc.
https://www.globenewswire.com/news-release/2024/07/04/2908712/0/en/Rafarma-pharmaceutical-updates-registration-of-Rafarma-microspheres-in-South-Korea.html
hyperboy262626
1 year ago
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.
Due to the changed geopolitical situation, the company was unable to complete the review of some of the assets that were set for audit consolidation, namely Kraspharma and Bebig. The Company will continue to provide its shareholders with regular unaudited financial statements of Kraspharma and Bebig. Once the geopolitical climate changes, the company intends to complete the audit of these two assets and add them to the consolidated audited accounts.
Meanwhile, the company is working on and acquiring several assets and projects located in Kazakhstan, Israel, El Salvador, Sri Lanka and Hong Kong.
The company is currently working with its auditor and will submit standard GAAP audit reports that will include the acquired assets. Announcements will also be made in the near future describing newly acquired assets and projects in which the company is involved.
New acquisitions will not dilute the current assets of the company's shareholders.
The recapitalization of the company will be carried out through preferred shares. Our goal is to restructure the company to expand our products and manufacturing capabilities into global markets while maintaining the original scale of operations.
We are going to focus on medical research and development, both in terms of devices and drugs. In addition, we are interested in creating partnerships to continue to benefit from new product launches. We hope to use the resulting innovative products to create a global innovative company worth at least $2 billion by the end of 2025.
After assessing market changes and ongoing research projects in recent years, the company's development directions until 2028 were formed. Its portfolio includes nuclear medicine, biotechnology products, SMART packaging, and biotechnology research and development.
Below is the company's strategy for 2023-2028:
1. Transfer of projects and experience to open markets. Instead of unsafe transactions with Russian assets, we transferred our experience to more stable markets. Production lines are moving to Hong Kong, Kazakhstan, South Korea, El Salvador and Sri Lanka;
2. Stopping the project in Uzbekistan. The project in Uzbekistan has been stopped until the legislation is clarified. The project is temporarily frozen, since the government of Uzbekistan has not yet begun to implement the decree of the President of the Republic on the commercial circulation of blood plasma, issued under our agreement. In this regard, we officially do not have the right to implement our project in Uzbekistan, but we are actively looking for a similar country in Central Asia;
3. Introduction of microspheres as medical devices in China and Korea. We continue to seek acquisitions in the global market to further expand our portfolio;
4. Completion of verification. The company expects that, taking into account the forced changes in its structure, the audit will be completed by the end of first quarter of 2024;
5. Additional investments. The company's management invests its own funds in the implementation of new projects by increasing the company's attracted capital without increasing the number of voting shares;
6. We plan to further capitalize and increase the profitability of existing assets:
?Medical polymers;
?Pharmaceutical substances and antibodies;
?Photopolymers and holographic products;
?Consumables for muon spectrography;
?Emulsion and colloidal photographic materials;
?Ultra-pure materials based on aluminum A5H and A6H (99.9999%) for microelectronics;
?Packaging materials for pharmaceuticals.
Rafarma has the potential to become a major driver of the modern healthcare industry in areas where we can do it best. We provide nuclear, technology and pharmaceutical solutions to hundreds of thousands of patients around the world. Our products are trusted by healthcare professionals and institutions around the world. Through a diversified product portfolio and a wide range of research projects, we strive to disseminate our work and our core values.
We believe that our commitment to saving and preserving the quality of life of patients, as well as the experience of our team, is the right combination to overcome this technological milestone. We focus on the areas we know best: nuclear medicine, new pharmaceuticals, medical devices and cancer treatment technologies. Our credo: we must save lives that should not be lost thanks to modern technological advances; we must preserve a quality of life that can be freed from unnecessary restrictions and suffering; and we must push medical progress forward.
The press conference with with shareholders hold on November 23, 2023 online on Zoom.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Investorr
3 months ago
Hot Features
Premium
